Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATENT-2 long-term extension of BAY 63-2521 in pulmonary arterial hypertension
NL-OMON35533Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of riociguat in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Bayer. Primary endpoint: Safety and tolerability of long-term riociguat treatment. Started Mar 2009; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON35533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35533.